Lotronex alosetron selective 5-HT3 receptor antagonist regulatory update

At the request of the FDA, GLXO withdrew Lotronex from the U.S. market to treat diarrhea-predominant irritable bowel syndrome (IBS) in women. GLXO also said it may relinquish approval licenses and wit...